Jinxin Fertility Group Ltd
HKEX:1951

Watchlist Manager
Jinxin Fertility Group Ltd Logo
Jinxin Fertility Group Ltd
HKEX:1951
Watchlist
Price: 2.8 HKD -2.1% Market Closed
Market Cap: 7.7B HKD
Have any thoughts about
Jinxin Fertility Group Ltd?
Write Note

Jinxin Fertility Group Ltd
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jinxin Fertility Group Ltd
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Jinxin Fertility Group Ltd
HKEX:1951
Other Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
Other Liabilities
ÂĄ23.9m
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Topchoice Medical Co Inc
SSE:600763
Other Liabilities
ÂĄ15.1m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanjing Xinjiekou Department Store Co Ltd
SSE:600682
Other Liabilities
ÂĄ159m
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
23%
Dian Diagnostics Group Co Ltd
SZSE:300244
Other Liabilities
ÂĄ526.7m
CAGR 3-Years
96%
CAGR 5-Years
15%
CAGR 10-Years
54%
Meinian Onehealth Healthcare Holdings Co Ltd
SZSE:002044
Other Liabilities
ÂĄ21.6m
CAGR 3-Years
-38%
CAGR 5-Years
-30%
CAGR 10-Years
-3%
No Stocks Found

Jinxin Fertility Group Ltd
Glance View

Market Cap
7.7B HKD
Industry
Health Care

Jinxin Fertility Group Ltd., a prominent player in the assisted reproduction market, has woven its narrative into the tapestry of modern healthcare by addressing a universal yet profoundly personal concern—fertility. Headquartered in China, this company has emerged at the forefront of fertility services, providing a comprehensive suite of offerings that include in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET), among other reproductive technologies. Operating in a market driven by societal shifts such as later-life family planning and increased urbanization, Jinxin Fertility has positioned itself strategically to capitalize on the growing demand for fertility treatments. Through its vast network of clinics across China and in key locations overseas, the company draws a diverse clientele seeking advanced reproductive assistance. What distinguishes Jinxin Fertility Group in this competitive landscape is its blend of cutting-edge technology and high-quality medical expertise. The company invests heavily in research and development to enhance its medical processes, ensuring high success rates and customer satisfaction. This approach not only solidifies its reputation as a trusted provider of fertility solutions but also translates into substantial profitability as clients are willing to invest in reliable and effective treatments for the chance at parenthood. Revenue streams flow from several channels, with core earnings derived from treatment and consultation fees, while ancillary services like genetic testing and cryopreservation contribute additional income. This multifaceted business model not only reinforces Jinxin Fertility’s financial robustness but also underscores its commitment to supporting hopeful parents through every step of their fertility journey.

Intrinsic Value
4.7 HKD
Undervaluation 40%
Intrinsic Value
Price

See Also

Back to Top